ArticleAmerican journal of translational research2022
MiR-762 regulates the activation of PI3K/AKT and Hippo pathways involved in the development of gastric cancer by targeting LZTS1.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets.Discover oncology · 2025Review
- Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells.Cancer cell international · 2025Article
- Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.Non-coding RNA research · 2025Review
- The possible correlation between miR-762, Hippo signaling pathway, TWIST1, and SMAD3 in lung cancer and chronic inflammatory diseases.Scientific reports · 2024Article
- The Role of the Dysregulation of Long Non-Coding and Circular RNA Expression in Medulloblastoma: A Systematic Review.Cancers · 2023Review
- Circ_0003356 suppresses gastric cancer growth through targeting the miR-668-3p/SOCS3 axis.World journal of gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMiR-762 has been confirmed as a tumor promoter in multiple tumors, while few reports illustrate its role in gastric cancer (GC). Thus, this research aimed to investigate whether miR-762 is involved in GC development.
methodsMiR-762 expression in the tumor tissues from GC patients and GC cell lines was analyzed by qRT-PCR. The assays including CCK-8, transwell, and flow cytometry were performed to reveal the functions of miR-762 in GC. The target genes of miR-762 were searched by online databases, and then were verified by dual-luciferase reporter assay. Western blot was performed to investigate the activation of PI3K/AKT and Hippo pathways in GC.
resultsMiR-762 was aberrantly upregulated in the tumor tissues and cell lines, and miR-762 silencing could effectively reduce the viability and promote apoptosis of GC cell lines. The study identified LZTS1 as a target gene of miR-762. It was also found that the effects of miR-762 on GC cells could be reversed by LZTS1, and miR-762 could upregulate the activation of the PI3K/AKT pathway but inhibit the Hippo pathway by targeting LZTS1.
conclusionMiR-762 activates PI3K/AKT and suppresses Hippo pathways to boost GC proliferation and invasion by targeting LZTS1.
Indexed as
Identifiers
35958482PMC9360834W4291675306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.